Editas Medicine Inc.股价跌至52周新低，触及1.27美元，较52周高点11.58美元大幅下跌89%。这家生物科技公司目前市值仅为1.06亿美元，尽管其资产负债表健康，现金多于债务，但仍面临市场逆风。这一最新价格较之前的估值显著下降，反映出过去一年88%的急剧下跌。投资者对公司前景持谨慎态度，导致持续抛售，最终达到这一新低。根据 InvestingPro ...

Truist and Stifel downgraded Editas Medicine Inc (NASDAQ:EDIT) to "hold" from "buy". While Truist removed its price target ...

The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug ...

The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to ...

Update (10:35 AM): Adds analysts views. Editas Medicine (NASDAQ:EDIT) plans to slash around 180 jobs, or approximately 65% of ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies ...

马萨诸塞州剑桥 - 目前市值约1.57亿美元的基因编辑公司Editas Medicine, Inc. (NASDAQ:EDIT)宣布战略转型,优先发展其体内CRISPR基因编辑项目,此举源于近期临床前研究的成功。该公司计划将现金储备延长至2027年第二季度,并计划在约两年内实现体内治疗的人体概念验证。根据 InvestingPro ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.08, a high estimate of $13.00, ...

Blackstone and its BioMed Realty affiliate have paid $250M to acquire three Kendall Square life sciences buildings. The deal ...

Truist Financial downgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a buy rating to a hold rating in a ...

Transitioning to a fully in vivo company strategically positions Editas Medicine to expand its therapeutic possibilities and aims for human proof of concept within approximately two years.